SCHEMBL8624016

SCHEMBL8624016

O=Cc1cc(Cc2n[nH]c(=O)c3cccc(N=O)c23)ccc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 17/20 0.46
LMNA P02545 1/20 0.43
ENPP1 P22413 1/20 0.41
AR P10275 2/20 0.41
TNKS O95271 1/20 0.40
ADORA1 P30542 1/20 0.40
CDK6 Q00534 1/20 0.40
PDE3A Q14432 1/20 0.40
PARP6 Q2NL67 1/20 0.40
PARP15 Q460N3 1/20 0.40
PARP14 Q460N5 1/20 0.40
PARP10 Q53GL7 1/20 0.40
TIPARP Q7Z3E1 1/20 0.40
PARP8 Q8N3A8 1/20 0.40
PARP16 Q8N5Y8 1/20 0.40
PARP12 Q9H0J9 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
PARP11 Q9NR21 1/20 0.40
PARP2 Q9UGN5 1/20 0.40
PARP4 Q9UKK3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8626052 0.92 LMNA (0.43) PARP1LMNAENPP1ARTNKS
SCHEMBL8626311 0.82 PARP1 (0.44) PARP1LMNAENPP1ARTNKS
SCHEMBL6742188 0.82 LMNA (0.64) PARP1LMNAENPP1AR
SCHEMBL30364517 0.82 LMNA (0.64) PARP1LMNAENPP1AR
SCHEMBL8624105 0.74 PARP1 (0.42) PARP1LMNAENPP1ARTNKS
SCHEMBL8629627 0.72 PARP1 (0.77) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL19748902 0.72 PARP1 (0.68) PARP1LMNAENPP1AR
SCHEMBL29655253 0.72 PARP1 (0.68) PARP1LMNAENPP1AR
SCHEMBL4584402 0.70 PARP1 (0.64) PARP1LMNAENPP1AR
SCHEMBL8153981 0.70 PARP1 (0.55) PARP1LMNAENPP1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129855-A1 PHTHALAZINONE DERIVATIVES MENEAR KEITH ALLAN (GB) 2012-05-24 US disclosed
US-20090192156-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192156-A1 PHTHALAZINONE DERIVATIVES CBR1, CBR3, SDHA PARP1 1973/4885LMNA 1059/4885ENPP1 4189/4885
US-20120129855-A1 PHTHALAZINONE DERIVATIVES CBR1, CBR3, SDHA PARP1 1973/4885LMNA 1059/4885ENPP1 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.